• Factors that could cause actual results to differ materially from those implied by these forward-looking statements include, but are not limited to:  The final amount of charges resulting from the planned North American asset realignment and the Company’s ability to realize anticipated savings and operational benefits from the asset realignment;  Our ability to achieve the strategic and other objectives relating to the acquisition of Spartech Corporation, including any expected synergies;  Our ability to successfully integrate Spartech and achieve the expected results of the acquisition, including, without limitation, the acquisition being accretive;  Disruptions, uncertainty or volatility in the credit markets that could adversely impact the availability of credit already arranged and the availability and cost of credit in the future;  The financial condition of our customers, including the ability of customers (especially those that may be highly leveraged and those with inadequate liquidity) to maintain their credit availability;  The speed and extent of an economic recovery, including the recovery of the housing market;  Our ability to achieve new business gains;  The effect on foreign operations of currency fluctuations, tariffs, and other political, economic and regulatory risks;  Changes in polymer consumption growth rates in the markets where we conduct business;  Changes in global industry capacity or in the rate at which anticipated changes in industry capacity come online;  Fluctuations in raw material prices, quality and supply and in energy prices and supply;  Production outages or material costs associated with scheduled or unscheduled maintenance programs;  Unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters;  An inability to achieve or delays in achieving or achievement of less than the anticipated financial benefit from initiatives related to working capital reductions, cost reductions, employee productivity goals, and an inability to raise or sustain prices for products or services;  An inability to raise or sustain prices for products or services;  An inability to maintain appropriate relations with unions and employees;  The inability to achieve expected results from our acquisition activities;  Our ability to continue to pay cash dividends;  The amount and timing of repurchases of our common shares, if any; and  Other factors affecting our business beyond our control, including, without limitation, changes in the general economy, changes in interest rates and changes in the rate of inflation. • The above list of factors is not exhaustive. • We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.

In particular, these include statements relating to future actions; prospective changes in raw material costs, product pricing or product demand; future performance; estimated capital expenditures; results of current and anticipated market conditions and market strategies; sales efforts; expenses; the outcome of contingencies such as legal proceedings and environmental liabilities; and financial results. Factors that could cause actual results to differ materially from those implied by these forward-looking statements include, but are not limited to: • Disruptions, uncertainty or volatility in the credit markets that could adversely impact the availability of credit already arranged and the availability and cost of credit in the future; • The effect on foreign operations of currency fluctuations, tariffs and other political, economic and regulatory risks; • Changes in laws and regulations regarding plastics in jurisdictions where we conduct business; • Fluctuations in raw material prices, quality and supply, and in energy prices and supply; • Production outages or material costs associated with scheduled or unscheduled maintenance programs; • Unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters; • Our ability to achieve strategic objectives and successfully integrate acquisitions, including Avient Protective Materials (APM); • An inability to raise or sustain prices for products or services; • Our ability to pay regular quarterly cash dividends and the amounts and timing of any future dividends; • Information systems failures and cyberattacks; • Amounts for cash and non-cash charges related to restructuring plans that may differ from original estimates, including because of timing changes associated with the underlying actions; and • Other factors affecting our business beyond our control, including without limitation, changes in the general economy, changes in interest rates, changes in the rate of inflation, any recessionary conditions, and terrorism or hostilities Use of Non-GAAP Measures This presentation includes the use of both GAAP (generally accepted accounting principles) and non-GAAP financial measures.

Change in Pension Value and Nonqualified Deferred Compensation Earnings (column (h)) The amounts reported in the “Change in Pension Value and Nonqualified Deferred Compensation Earnings” column for 2015 are comprised entirely of changes in pension values between December 31, 2014 and December 31, 2015. Newlin terminates employment for good reason following a change of control of PolyOne. For this purpose, a “change of control” is defined in the Long-Term Incentive Plan.

• Review and approve the terms of all employment agreements, management continuity agreements and change in control agreements for elected officers. 3 Non-employee Director Compensation. • Review the compensation of non-employee directors and make recommendations to the Board regarding changes to existing compensation levels. • Perform administrative functions with respect to the compensation of non-employee directors, including interpreting existing policy. • Review and approve (or approve and recommend to the Board for its approval) equity-based grants and awards to non-employee directors under the Company’s equity-based plans. However, the Committee shall meet regularly without such members present, and in all cases the Chief Executive Officer and any other such officers shall not be present at meetings at which their individual compensation or performance is discussed or determined. • The Committee may appoint subcommittees from time to time as needed, each of which will have the specific duties and responsibilities delegated to it by the Committee. • The Committee may delegate its authority under this Charter relating to employees other than executive officers and non-employee directors, to the extent it deems appropriate and consistent with law and customary practice, and may otherwise fully delegate authority relating to matters it deems to be ministerial. • The Committee may delegate its authority under this Charter relating to employee benefit plans in which executive officers participate if such employee benefit plans are broad-based, to the extent it deems appropriate and consistent with law and customary practice. • The Corporate Secretary or designee will be responsible for keeping minutes of the Committee meetings. • The Committee will meet at least four times a year and at such other times as may be requested by the Committee Chair. • The Committee will annually review its charter and recommend any changes to the Nominating and Governance Committee.

HITTING THE SWEET SPOT FOR ARCHERY ENTHUSIASTS SPECIALTY MATERIALS AND UPGRADED DESIGN ACHIEVE GAME-CHANGING PRECISION © 2022, All Rights Reserved Avient Corporation, 33587 Walker Road, Avon Lake, Ohio USA 44012 Interested in learning more about specialty TPEs or advancing your design? This change reduced fatigue, which then resulted in less movement and a more precise shot.

KEY CHARACTERISTICS • Available for polyethylene, polypropylene, ABS, polycarbonate and styrenics • Bio-content of resin carrier varies from 70% to 100% depending on polymer—calculated to ASTM D6866 standard • Manufactured at four ISO 13485 certified sites, providing global consistency and security of supply • Documented change control beyond CAS number, reducing risk of change • Drop-in solutions that can be processed like fossil-based grades on common injection molding and extrusion machines • Can be provided as ready-to-use pre-colored or additive formulation REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 - USP and (incl. class VI) - European Pharmacopeia, monograph 3.1.3/ 3.1.5 (polyolefin packaging materials) - USP (polyethylene) - Elemental impurities as per ICH Q3D • Registered Drug Master File (Type III) and/or Device Master File • Food contact according to US FDA and APPLICATION BULLETIN Sustainability Spotlight Bio-polymers Healthcare use limitations apply—see below.

REGULATORY SUPPORT • Drug delivery devices • Pharmaceutical packaging • Medical equipment KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified sites, providing global consistency and increased security of supply • Documented change control beyond CAS number level, reducing the risk of change • Allows crystallization in semi-crystalline polymers to begin faster and complete earlier REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) and/or Device Master File • Food contact established with FDA/EU* APPLICATION BULLETIN * FDA/EU compliance information available upon request Healthcare use limitations apply—see below.

KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified sites, providing global consistency and increased security of supply • Documented change control beyond CAS number level, reducing risk of change • Non-phthalate and formulated without animal-derived substances • Different tones of amber available on request —more or less red or yellow and/or lighter or darker • Also available in liquid form REGULATORY SUPPORT • Pre-tested raw materials: - ISO 10993-1 and USP parts (Class VI) - European Pharmacopeia, monograph 3.1.15, USP and elemental analysis as per ICH Q3D - USP criteria appearance of solution, color • Registered Drug Master File (Type III) by the FDA • Food contact compliance established with FDA/EU* • YBB00102002-2015 (oral liquid pharmaceutical PET bottles) compliance support APPLICATION BULLETIN * FDA/EU compliance information available upon request Healthcare use limitations apply—see below.

Compliance Programs • At least annually review the programs and procedures established by the Company that monitor compliance with the Company’s policies, standards and practices, and laws and regulations with respect to safety, health, environmental, physical security and product stewardship, including providing oversight of the systems that are in place to monitor and mitigate the Company’s carbon footprint and physical risks associated with climate change; • Periodically review with management the significant safety, health, environmental, physical security, and product stewardship risks or exposures faced by the Company, if any, and steps taken by management to minimize such risks and exposures to the Company and its constituencies; • At least annually review the status of the Company’s environmental and safety audit process, assessing compliance with Company policies, standards, practices, laws and regulations; and • Periodically review claims, demands, administrative orders and legal proceedings against the Company regarding safety, health, environmental, physical security and product stewardship matters. Committee Meetings and Action • A majority of the Committee members will be a quorum for the transaction of business. • The action of a majority of those present at a meeting at which a quorum is present will be the act of the Committee. • Any action that may be taken at a meeting of the Committee may be taken by written consent so long as the written consent is unanimously approved and filed with the Corporate Secretary. • The Company’s Senior Vice President, Global Operations and Process Improvement or his/her designee, will be the management liaison to the Committee. • The Committee may appoint subcommittees from time to time as needed, and may delegate authority to such subcommittees or to officers of the Company when appropriate, consistent with applicable laws, regulations and listing standards. • The Corporate Secretary or his/her designee shall be responsible for keeping minutes of the Committee meetings. • The Committee will meet at least two times a year and at such other times as may be requested by its Chair. 3 • The Committee will annually review its charter and recommend any changes to the Governance and Corporate Responsibility Committee.

url=https%3A%2F%2Fwww.cbp.gov%2Ftrade%2Fforced-labor&data=05%7C01%7Cjacqueline.thomson%40avient.com%7Ca0427e02fa1b4b576fe208db6dac207e%7C7bc21b5c83b04482be9e2825d33c1759%7C0%7C0%7C638224359373869329%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=xxFjS7ADNXRYgriLexntpLUCOyllzLGactoRmj2EoCE%3D&reserved=0 https://www.avient.com/sites/default/files/2020-10/avient-conflict-minerals-policy-10.2020.pdf https://www.avient.com/sites/default/files/2020-10/avient-conflict-minerals-policy-10.2020.pdf • Engage in due diligence of supply chains by following a nationally or internationally recognized due diligence framework; • Upon request, report to Avient on its due diligence process and certify that 3TG metals supplied to Avient from the Covered Countries are conflict free; and • Promptly report to Avient any supply chain changes regarding the origin of 3TG metals or conflict status. • Enable employees and other stakeholders to report questions or concerns related to your business, people or products. • Uphold freedom of association and the right to collective bargaining in accordance with applicable laws. External communications about Avient require Avient’s prior written consent. • Inform Avient of financial, economic, supply changes (including origin or conflict status of 3TG metals), government regulations or other materials conditions that could affect ongoing operations or operating decisions, or if the company has been debarred as a government contractor. • Establish an information security and data privacy system to protect Avient’s information, including information of its customers and employees, from being disclosed, changed, destroyed, or used for any purpose other than the purpose for which it was provided.